Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-011471
Filing Date
2025-08-14
Accepted
2025-08-14 07:05:53
Documents
56
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q plx-20250630x10q.htm   iXBRL 10-Q 1064979
2 EX-31.1 plx-20250630xex31d1.htm EX-31.1 12466
3 EX-31.2 plx-20250630xex31d2.htm EX-31.2 12634
4 EX-32.1 plx-20250630xex32d1.htm EX-32.1 6706
5 EX-32.2 plx-20250630xex32d2.htm EX-32.2 6728
6 GRAPHIC plx-20250630x10q005.jpg GRAPHIC 84996
7 GRAPHIC plx-20250630x10q006.jpg GRAPHIC 58451
8 GRAPHIC plx-20250630x10q007.jpg GRAPHIC 52258
9 GRAPHIC plx-20250630x10q008.jpg GRAPHIC 38391
10 GRAPHIC plx-20250630x10q009.jpg GRAPHIC 56626
11 GRAPHIC plx-20250630x10q010.jpg GRAPHIC 40218
  Complete submission text file 0001558370-25-011471.txt   5169653

Data Files

Seq Description Document Type Size
12 EX-101.SCH plx-20250630.xsd EX-101.SCH 29134
13 EX-101.CAL plx-20250630_cal.xml EX-101.CAL 43637
14 EX-101.DEF plx-20250630_def.xml EX-101.DEF 106650
15 EX-101.LAB plx-20250630_lab.xml EX-101.LAB 219397
16 EX-101.PRE plx-20250630_pre.xml EX-101.PRE 178873
59 EXTRACTED XBRL INSTANCE DOCUMENT plx-20250630x10q_htm.xml XML 610855
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33357 | Film No.: 251214253
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)